Skip to main content

Table 7 Clinicopathological parameters analysis according to rs1966265 genetic polymorphism in breast cancer patients

From: Effects of FGFR gene polymorphisms on response and toxicity of cyclophosphamide-epirubicin-docetaxel-based chemotherapy in breast cancer patients

Clinicopathological parameters rs1966265(N = 90)
GG AG &AA OR 95%CI P
T-status,n(%)
  ≤ T2 3(3.3) 3(3.3)    
  > T2 17(18.9) 67(74.4) 3.941 0.730–21.284 0.111
N-status,n(%)
 N0+ N1 15(6.7) 55(61.1)    
 N2+ N3 5(5.6) 15(16.7) 0.818 0.256–2.615 0.735
Tumor grade
 GradeII 8(8.9) 26(28.9)    
 GradeIII 12(13.3) 44(48.9) 1.128 0.408–3.121 0.816
ER
 positive 16(17.8) 46(51.1)    
 negative 4(4.4) 24(26.7) 2.087 0.628–6.941 0.230
PR
 positive 13(14.4) 38(42.2)    
 negative 7(7.8) 32(35.6) 1.564 0.557–4.390 0.396
Her2-neu stastus
 positive 7(7.8) 25(27.8)    
 negative 13(14.4) 45(50.0) 0.969 0.342–2.744 0.953
TNBC
 Yes 3(3.3) 13(14.4)    
 No 17(18.9) 57(63.3) 1.292 0.328–5.072 0.713
P63
 positive 2(2.2) 1(1.1)    
 negative 18(20.0) 69(76.7) 7.667 0.658–89.367 0.104
Ki-67
 positive 3(3.3) 25(27.8)    
 negative 17(18.9) 45(50.0) 0.318 0.085–1.190 0.089
  1. T tumor stage, N nodes stage, TNBC triple negative breast cancer, Her 2 human epidermal growth factor receptor 2